Sanofi S.A. (SNY)
Nasdaq · Paris, France · Founded 1973 · CEO Olivier Charmeil
Valuation summary
$132.16 fair value versus $46.06 in the market, a difference of +186.9%. Rated Strong Buy.
| Fair value per share | $132.16 |
| Current share price | $46.06 |
| Upside / downside | +186.9% |
| Bear case | $84.97 |
| Bull case | $200.48 |
| Discount rate (WACC) | 8.4% |
| Terminal growth | 2.40% |
| Market capitalisation | $104B |
| EV / Sales | 1.9x |
About Sanofi S.A.
Traces to 1973, taking its current form through mergers with Synthélabo and Aventis. Olivier Charmeil took over as chief executive in 2026, succeeding Paul Hudson, who had refocused the company on immunology and vaccines and spun off consumer healthcare. Note that the US listing is an ADS: one ordinary Paris-listed share represents two ADSs, so the share count here is stated in ADSs to match the quoted price. Dupixent, an anti-inflammatory treating eczema, asthma and several other conditions, has become one of the largest-selling drugs in the world and drives most of the growth. US-listed as an ADR.
Investment case
- Dupixent keeps adding approved indications, each expanding the addressable population.
- Vaccines is a structurally defensive business with high barriers to entry.
- Trades at a discount to US pharmaceutical peers on comparable pipelines.
Key risks
- Heavy dependence on a single product — Dupixent is a very large share of growth.
- European pharmaceutical companies face persistent pricing pressure at home.
- The pipeline behind Dupixent is less proven than the market would like, and the October 2026 Regeneron deal adds $1 billion upfront and up to $7 billion in milestones for mostly early-stage antibodies.
Recent developments
- 2026-10-30 · Q3 sales up 14.3% at constant currency to EUR14.4bn and business EPS up 22%; Dupixent up 35% to EUR5.7bn and 2026 guidance upgraded source
- 2026-10-06 · Sanofi will publish third-quarter 2026 results on 30 October 2026. source
- 2026-10-01 · Sanofi will pay Regeneron $1bn upfront, plus up to $7bn in milestones, to co-develop next-generation long-acting immunology antibodies; prior litigation settled. source
- 2026-09-14 · Sanofi agreed to transfer 20 mature medicines and three plants to Cheplapharm in exchange for a 26.4% equity stake; completion expected by Q3 2027. source
Revenue by segment
| Dupixent & Immunology | 42% |
| Vaccines | 24% |
| General Medicines | 26% |
| Consumer & Other | 8% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $73.2B | $12.5B |
| Year 2 | $82.3B | $14.0B |
| Year 3 | $91.7B | $15.6B |
| Year 4 | $101.2B | $17.1B |
| Year 5 | $110.7B | $18.7B |
What the street says
Generally viewed as reasonably valued with real single-product concentration risk. The October 2026 expansion of the Regeneron alliance into long-acting successors to Dupixent is read as an attempt to extend the franchise, while the planned transfer of 20 mature medicines to Cheplapharm continues the narrowing of the portfolio.
Comparable companies: MDT · ABT · SYK · IDXX · TMO · BSX · AZN · ISRG
Open the interactive model, price chart and sensitivity grid →